氨溴特罗联合孟鲁司特对儿童咳嗽变异性哮喘的症状评分和肺功能的影响

摘要

Objective To evaluate the influence of ambroxol hydrochloride and clenbuterol hydrochloride on children cough variant asthma symptoms score and lung function.Methods 90 children with cough variant asthma ( CVA ) were randomly divided into group A, B and C, with each group 30 cases.Group A was given montelukast - na, group B was given montelukast - na combined with ambroxol hydrochloride and clenbuterol hydrochloride, and group C was given ambroxol hydrochloride and clenbuterol hydrochlorid.The changes of asthma control test score ( C - ACT ) and pulmonary function ( PEF mutation rate ) were observed in the three groups after treatment.Results After two weeks' treatment, the asthma control test score in group B was significantly higher than that in group A and group C ( P ＜ 0.05 ), and the PEF mutation rate in group B was significantly lower than that in group A and group C ( P ＜0.05 ), but there's no significant difference between group A and group C in both the asthma control test score and the PEF mutation rate ( P ＞0.05 ).After four weeks' treatment, the asthma control test score and the PEF mutation rate in group A, group B and group C showed no statistically significant differences ( P ＞0.05 ).Conclusion Ambroxol hydrochloride and clenbuterol hydrochloride can significantly improve C - ACT score and lung function in children with CVA, and the combined use with montelukast - na has super-imposition effect.%目的 评价氨溴特罗联合孟鲁司特对儿童咳嗽变异性哮喘(CVA)的症状评分和肺功能的影响.方法将90例CVA患儿随机分为A、B、C 3组,每组30例.A组给予孟鲁司特治疗,B组给予孟鲁司特联合氨溴特罗治疗,C组给予氨溴特罗治疗.观察3组治疗后的哮喘控制测试评分(C-ACT)及肺功能(PEF变异率)的改变.结果 治疗后2周B组C-ACT评分明显高于A组和C组,差异均有统计学意义( P ＜0.05);A组和C组比较差异无统计学意义( P ＞0.05).治疗后4周C-ACT评分A、B、C 3组比较差异无统计学意义( P ＞0.05).治疗后2周PEF变异率B组明显低于A组和C组,差异均有统计学意义( P ＜0.05);A组和C组比较差异无统计学意义( P ＞0.05).治疗后4周PEF变异率A、B、C 3组比较差异无统计学意义( P ＞0.05).结论 氨溴特罗能显著改善CVA患儿的C-ACT评分和肺功能,与孟鲁司特联合使用,有叠加作用.